HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load
- PMID: 11722270
- DOI: 10.1001/jama.286.20.2560
HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load
Abstract
Context: It is unclear whether delay in initiation of antiretroviral therapy (ART) may lead to a poorer viral load response for patients with human immunodeficiency virus (HIV).
Objective: To characterize the relationship of viral load response to ART with baseline CD4 cell count and baseline viral load.
Design: Inception cohort of 3430 therapy-naive patients with HIV, of whom 3226 patients had at least 1 viral load count after the start of ART.
Setting: Three cohort studies of patients cared for in HIV clinics in Europe between 1996 and 2000.
Patients: All patients initiating ART consisting of at least 3 drugs initiated in or after 1996 and for whom CD4 cell count and viral load were available in the prior 6 months (at most).
Main outcome measures: Viral load decrease to below 500 copies/mL; viral load rebound to above 500 copies/mL (2 consecutive values).
Results: Of 3226 patients during the median follow-up of 119 weeks, 2741 (85%) experienced viral suppression to less than 500 copies/mL by 32 weeks. Relative hazards (RHs) of achieving this were 1.08 (95% confidence interval [CI], 0.98-1.21) and 0.94 (95% CI, 0.84-1.04) for baseline CD4 cell counts between 200 and 349 x 10(6)/L and baseline CD4 cell counts lower than 200 x 10(6)/L, respectively, compared with baseline CD4 cell counts of 350 x 10(6)/L or higher, after adjustment for several factors including baseline viral load. For baseline viral load, the RHs were 0.95 (95% CI, 0.84-1.07) and 0.65 (95% CI, 0.58-0.74), for 10 000 to 99 999 and 100 000 copies/mL or greater, respectively, compared with less than 10 000 copies/mL, but the probability of viral load lower than 500 copies/mL at week 32 was similar in all 3 groups. Subsequent rebound above 500 copies/mL was no more likely with a lower baseline CD4 cell count or higher viral load.
Conclusion: In this study, lower CD4 cell counts and higher viral loads at baseline were not associated with poorer virological outcome of ART. Those with baseline viral loads of greater than 100 000 copies/mL had a slower rate of achieving viral suppression.
Comment in
-
Initiating antiretroviral therapy during HIV infection: confusion and clarity.JAMA. 2001 Nov 28;286(20):2597-9. doi: 10.1001/jama.286.20.2597. JAMA. 2001. PMID: 11722276 No abstract available.
Similar articles
-
Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy.JAMA. 2001 Nov 28;286(20):2568-77. doi: 10.1001/jama.286.20.2568. JAMA. 2001. PMID: 11722271
-
Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005.Clin Infect Dis. 2007 Aug 1;45(3):381-90. doi: 10.1086/519428. Epub 2007 Jun 26. Clin Infect Dis. 2007. PMID: 17599319
-
Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment.HIV Med. 2007 Jan;8(1):46-54. doi: 10.1111/j.1468-1293.2007.00427.x. HIV Med. 2007. PMID: 17305932
-
[Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].Enferm Infecc Microbiol Clin. 2009 Apr;27(4):222-35. doi: 10.1016/j.eimc.2008.11.002. Epub 2009 Feb 26. Enferm Infecc Microbiol Clin. 2009. PMID: 19246124 Spanish.
-
[Predictive factors of virological response to primary antiretroviral treatment].Presse Med. 2004 Mar 13;33(5):310-5. doi: 10.1016/s0755-4982(04)98570-3. Presse Med. 2004. PMID: 15041876 Review. French.
Cited by
-
Viral load undetectable state and predictors among children and adolescents living with HIV in South Gondar, Ethiopia, 2023: an 8-year retrospective cohort study.BMJ Open. 2024 Oct 26;14(10):e083206. doi: 10.1136/bmjopen-2023-083206. BMJ Open. 2024. PMID: 39461862 Free PMC article.
-
Determinants of virological failure among HIV clients on second-line antiretroviral treatment at Felege-hiwot and University of Gondar comprehensive specialized hospitals in the Amhara Region, Northwest Ethiopia: A case-control study.PLoS One. 2024 Jul 9;19(7):e0289450. doi: 10.1371/journal.pone.0289450. eCollection 2024. PLoS One. 2024. PMID: 38980874 Free PMC article.
-
Low-Level Viremia among Adults Living with HIV on Dolutegravir-Based First-Line Antiretroviral Therapy Is a Predictor of Virological Failure in Botswana.Viruses. 2024 May 1;16(5):720. doi: 10.3390/v16050720. Viruses. 2024. PMID: 38793602 Free PMC article.
-
Efficacy of Dolutegravir versus Darunavir in Antiretroviral First-Line Regimens According to Resistance Mutations and Viral Subtype.Viruses. 2023 Mar 16;15(3):762. doi: 10.3390/v15030762. Viruses. 2023. PMID: 36992471 Free PMC article.
-
Toxoplasma gondii, HBV, and HCV co-infection and their correlation with CD4 cells among Iranian HIV-positive patients.Immun Inflamm Dis. 2023 Feb;11(2):e794. doi: 10.1002/iid3.794. Immun Inflamm Dis. 2023. PMID: 36840494 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
